The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis

Zhang, Beilei; Zhou, Fengyan; Hong, Jiaze; Ng, Derry Minyao; Yang, Tong; Jin, Jiyuan; Zhou, Feifei; Chen, Ping; Xu, Yunbao

doi:10.1186/s12957-021-02291-6

Cited by 22 publications

(16 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PNP SN38–DOTAP was also effective in killing cancer cells from other xenograft cancer models such as the BxPC-3 pancreatic cancer. 37 As shown in Fig. 2I–K, the tumor growth rate and T/C% of PNP SN38–DOTAP was also significantly lower than that of CPT-11.…”

Section: Resultsmentioning

confidence: 81%

Lipid-assisted PEG-b-PLA nanoparticles with ultrahigh SN38 loading capability for efficient cancer therapy

Huang,

Li,

Yang

et al. 2023

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 81%

Lipid-assisted PEG-b-PLA nanoparticles with ultrahigh SN38 loading capability for efficient cancer therapy

Huang,

Li,

Yang

et al. 2023

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

“…Neuropathy is a common adverse effect associated with gemcitabine-nab-paclitaxel and mFOLFIRINOX chemotherapy schemes [ 46 , 47 ]. On the other hand, DM is the most common cause of autonomic neuropathy; nevertheless, the pathophysiology of diabetic neuropathy is not fully understood, and its aetiology seems to be multifactorial [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma—Prevalence, Clinicopathological Variables, and Clinical Outcomes

Badowska-Kozakiewicz

Fudalej

Kwaśniewska

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: pancreatic ductal adenocarcinoma (PDAC) is the seventh leading cause of cancer-related deaths with increasing incidence and link to the onset of diabetes mellitus (DM). The aim of this study is to describe the prevalence of DM among patients with the diagnosis of PDAC, analyse the association between the occurrence of DM and clinicopathological factors, and detect variables influencing overall survival. Methods: a retrospective analysis of medical records was performed. The patients were divided into non-DM (n = 101) and DM (n = 74) groups. Statistical analysis with the usage of appropriate tests was conducted. Results: Patients in the groups of DM and NODM had significantly longer median OS than the non-DM group. Nodal involvement, tumour location, level of CEA, CRP and CRP/lymphocytes ratio were significantly associated with OS among patients with any type of DM. Neutropenia was less frequently observed in the DM group. Conclusions: DM is prevalent among patients with pancreatic cancer. In our study, patients with DM receiving palliative chemotherapy had significantly higher median OS than those without DM. The increased comprehension of the mechanisms of the relationship between DM and pancreatic cancer needs further research, which might provide avenues for the development of novel preventive and therapeutic strategies.

show abstract

“…Since compound 9 was cytotoxic, further chemical modification of this compound that enhances the TS value should be done. On the other hand, compound 7 , compound 15 , and 5-FU showed cytostatic growth inhibition, and their action may be potentiated through combination with other types of anticancer drugs [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

Tumor-Specificity, Neurotoxicity, and Possible Involvement of the Nuclear Receptor Response Pathway of 4,6,8-Trimethyl Azulene Amide Derivatives

Naitoh

Orihara

Sakagami

et al. 2022

IJMS

View full text Add to dashboard Cite

Background: Very few papers covering the anticancer activity of azulenes have been reported, as compared with those of antibacterial and anti-inflammatory activity. This led us to investigate the antitumor potential of fifteen 4,6,8-trimethyl azulene amide derivatives against oral malignant cells. Methods: 4,6,8-Trimethyl azulene amide derivatives were newly synthesized. Anticancer activity was evaluated by tumor-specificity against four human oral squamous cell carcinoma (OSCC) cell lines over three normal oral cells. Neurotoxicity was evaluated by cytotoxicity against three neuronal cell lines over normal oral cells. Apoptosis induction was evaluated by Western blot and cell cycle analyses. Results: Among fifteen derivatives, compounds 7, 9, and 15 showed the highest anticancer activity, and relatively lower neurotoxicity than doxorubicin, 5-fluorouracil (5-FU), and melphalan. They induced the accumulation of a comparable amount of a subG1 population, but slightly lower extent of caspase activation, as compared with actinomycin D, used as an apoptosis inducer. The quantitative structure–activity relationship analysis suggests the significant correlation of tumor-specificity with a 3D shape of molecules, and possible involvement of inflammation and hormone receptor response pathways. Conclusions: Compounds 7 and 15 can be potential candidates of a lead compound for developing novel anticancer drugs.

show abstract

The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis

Cited by 22 publications

References 58 publications

Lipid-assisted PEG-b-PLA nanoparticles with ultrahigh SN38 loading capability for efficient cancer therapy

Lipid-assisted PEG-b-PLA nanoparticles with ultrahigh SN38 loading capability for efficient cancer therapy

Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma—Prevalence, Clinicopathological Variables, and Clinical Outcomes

Tumor-Specificity, Neurotoxicity, and Possible Involvement of the Nuclear Receptor Response Pathway of 4,6,8-Trimethyl Azulene Amide Derivatives

Contact Info

Product

Resources

About